Mackay Shields LLC Reduces Holdings in Hologic, Inc. (HOLX)

Mackay Shields LLC decreased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 55.6% in the 4th quarter, HoldingsChannel reports. The fund owned 116,348 shares of the medical equipment provider’s stock after selling 145,883 shares during the quarter. Mackay Shields LLC’s holdings in Hologic were worth $4,782,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of HOLX. Oregon Public Employees Retirement Fund grew its stake in shares of Hologic by 3,960.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 1,192,649 shares in the last quarter. Capital International Investors acquired a new position in shares of Hologic in the third quarter worth $48,560,000. The Manufacturers Life Insurance Company grew its stake in shares of Hologic by 135.9% in the third quarter. The Manufacturers Life Insurance Company now owns 1,958,778 shares of the medical equipment provider’s stock worth $80,270,000 after acquiring an additional 1,128,328 shares in the last quarter. Man Group plc grew its stake in shares of Hologic by 453.6% in the third quarter. Man Group plc now owns 1,131,685 shares of the medical equipment provider’s stock worth $46,376,000 after acquiring an additional 927,244 shares in the last quarter. Finally, Capital World Investors grew its stake in shares of Hologic by 2.5% in the third quarter. Capital World Investors now owns 27,808,896 shares of the medical equipment provider’s stock worth $1,139,609,000 after acquiring an additional 671,524 shares in the last quarter. Institutional investors and hedge funds own 85.85% of the company’s stock.

Several research firms have commented on HOLX. BidaskClub upgraded shares of Hologic from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 21st. Piper Jaffray Companies boosted their price target on shares of Hologic to $49.00 and gave the stock an “overweight” rating in a research note on Thursday, January 31st. BTIG Research reiterated a “buy” rating and set a $50.00 target price on shares of Hologic in a research note on Thursday, January 31st. Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Thursday, February 21st. Finally, Morgan Stanley downgraded shares of Hologic from an “equal weight” rating to an “underweight” rating and lowered their target price for the stock from $44.00 to $39.00 in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, nine have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $44.52.

In other news, Director Sally Crawford sold 12,306 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $47.61, for a total value of $585,888.66. Following the sale, the director now directly owns 168,886 shares in the company, valued at $8,040,662.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Benjamin Jordan Cohn sold 6,830 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $46.70, for a total transaction of $318,961.00. Following the completion of the sale, the insider now owns 22,002 shares in the company, valued at $1,027,493.40. The disclosure for this sale can be found here. Insiders have sold 23,378 shares of company stock worth $1,105,836 over the last 90 days. 0.90% of the stock is currently owned by company insiders.

Shares of NASDAQ:HOLX opened at $47.30 on Thursday. Hologic, Inc. has a one year low of $35.10 and a one year high of $48.11. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.30 and a quick ratio of 0.91. The stock has a market capitalization of $13.82 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 2.23 and a beta of 0.75.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.01. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The business had revenue of $830.70 million during the quarter, compared to analysts’ expectations of $823.22 million. During the same period in the prior year, the company earned $0.55 earnings per share. The business’s revenue was up 5.0% compared to the same quarter last year. As a group, sell-side analysts predict that Hologic, Inc. will post 2.41 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.themarketsdaily.com/2019/03/21/mackay-shields-llc-reduces-holdings-in-hologic-inc-holx.html.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: Understanding Average Daily Trade Volume

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.